|
Patent landscape, scope, and claims: |
United States Patent 10,369,264: Scope, Claims, and Landscape Analysis
What is the core invention protected by U.S. Patent 10,369,264?
U.S. Patent 10,369,264, titled "Substantially Pure Amorphous Vorapaxar and Method of Preparation," claims the compound vorapaxar in a substantially pure amorphous form and specific methods for its preparation. Vorapaxar is a direct, reversible protease-activated receptor-1 (PAR-1) antagonist. The patent focuses on overcoming limitations of prior crystalline forms of vorapaxar, particularly regarding solubility and bioavailability.
The invention addresses the challenges associated with producing and formulating amorphous vorapaxar with high purity and stability. Amorphous forms of drugs generally exhibit improved solubility and dissolution rates compared to their crystalline counterparts, potentially leading to enhanced oral absorption and therapeutic efficacy. However, amorphous solids are thermodynamically less stable and can be prone to crystallization over time, reducing shelf life and drug performance. This patent aims to provide a solution to these inherent issues.
What are the key claims of U.S. Patent 10,369,264?
The patent contains 15 claims, including independent and dependent claims, detailing the protected subject matter.
Independent Claims:
-
Claim 1: This claim defines a substantially pure amorphous vorapaxar. The purity is specified as not less than 99.0% by weight. It also stipulates that the amorphous form is characterized by the absence of any crystalline forms of vorapaxar, determined by X-ray powder diffraction (XRPD). This claim is central to the patent, establishing the proprietary right over the amorphous form itself.
-
Claim 6: This claim recites a method for preparing substantially pure amorphous vorapaxar. The method involves dissolving vorapaxar in an organic solvent, adding a non-solvent to precipitate vorapaxar, and then isolating the precipitated vorapaxar. The key here is the control of precipitation conditions to yield the amorphous form.
-
Claim 11: This claim is directed to a pharmaceutical composition comprising the substantially pure amorphous vorapaxar as defined in claim 1 and at least one pharmaceutically acceptable excipient. This broadens the protection to include formulations containing the novel amorphous form.
Dependent Claims:
Dependent claims further refine and narrow the scope of the independent claims by adding specific limitations or embodiments. For example:
- Claims dependent on Claim 1 may specify particular ranges of residual solvent content or crystallinity levels.
- Claims dependent on Claim 6 may detail specific organic solvents, non-solvents, temperature ranges, or mixing ratios used in the preparation method. Examples of solvents mentioned in the specification (though not explicitly in the primary independent claims) include alcohols like ethanol, isopropanol, or methanol, and non-solvents like water or heptane. The precise combination and conditions are critical to achieving the desired amorphous state and purity.
- Claims dependent on Claim 11 may specify particular types of excipients, such as binders, disintegrants, fillers, or lubricants, and their relative amounts.
The claims are designed to protect the specific amorphous form of vorapaxar and the processes for its creation, as well as its inclusion in drug products. The emphasis on "substantially pure amorphous" and the explicit exclusion of crystalline forms are critical aspects of the patent's scope.
What is the prior art landscape for vorapaxar patents?
The patent landscape for vorapaxar is characterized by a series of patents covering its discovery, synthesis, crystalline forms, and therapeutic uses. U.S. Patent 10,369,264 builds upon this foundation by focusing on a specific, advantageous amorphous form.
Key areas of prior art include:
-
Composition of Matter Patents: Initial patents, such as those covering the vorapaxar molecule itself (e.g., U.S. Patent 6,703,399, assigned to Schering Corporation, now Merck & Co.), established the foundational intellectual property for the drug substance. These patents typically cover the chemical structure of the compound.
-
Crystalline Forms and Polymorphs: Following the discovery of vorapaxar, researchers identified and patented various crystalline forms (polymorphs). Polymorphs of a drug can have different physical properties, including solubility, stability, and melting point, which can impact its formulation and bioavailability. Prior art likely includes patents claiming specific crystalline forms of vorapaxar, such as the monohydrate or anhydrous crystalline forms. U.S. Patent 8,877,935, also assigned to Schering Corporation, is an example of a patent claiming a specific crystalline form of vorapaxar.
-
Methods of Synthesis: Patents also exist for different synthetic routes to produce vorapaxar. The inventiveness in U.S. Patent 10,369,264 lies not just in synthesizing vorapaxar, but in a method specifically designed to yield the amorphous form with high purity.
-
Therapeutic Uses and Formulations: Patents may also cover specific medical indications for which vorapaxar is used, as well as various pharmaceutical formulations (e.g., tablets, capsules) designed for its administration. The commercial product containing vorapaxar is Zontivity®, marketed by Merck & Co.
U.S. Patent 10,369,264's focus on the "substantially pure amorphous" form differentiates it from prior art that may have disclosed crystalline forms or less pure amorphous preparations. The patent's strength lies in the ability to demonstrate that this specific amorphous form possesses superior properties and that the claimed preparation methods are inventive and non-obvious over existing techniques for producing vorapaxar.
What are the potential implications of U.S. Patent 10,369,264 for market exclusivity?
U.S. Patent 10,369,264 provides a significant layer of market exclusivity for the amorphous form of vorapaxar. This patent directly impacts generic manufacturers seeking to enter the market with their own versions of vorapaxar-containing products.
-
Blocking Generic Entry: Generic drug manufacturers must design their products to avoid infringing on existing patents. If they wish to market a vorapaxar product utilizing the substantially pure amorphous form, they would likely need to obtain a license from the patent holder or challenge the validity of U.S. Patent 10,369,264.
-
Data Exclusivity and Orange Book: Vorapaxar is marketed as Zontivity® (vorapaxar tablets) by Merck & Co. The U.S. Food and Drug Administration (FDA) maintains the Approved Drug Products with Therapeutic Equivalence Evaluations List, commonly known as the Orange Book. Patents listed in the Orange Book for a particular drug product are crucial for understanding market exclusivity. U.S. Patent 10,369,264, once granted and listed, would contribute to the period of exclusivity for vorapaxar.
-
Patent Term: U.S. Patent 10,369,264 was filed on March 20, 2017, and granted on August 6, 2019. The standard patent term in the U.S. is 20 years from the filing date. Therefore, U.S. Patent 10,369,264 is expected to expire in March 2037, barring any extensions. However, patent term adjustments (PTA) or patent term extensions (PTE) due to regulatory review delays could extend this period.
-
Potential for Litigation: The existence of this patent creates a potential for patent litigation. Generic companies may attempt to design around the patent claims, develop alternative amorphous forms not covered by the patent, or challenge the patent's validity (e.g., on grounds of obviousness or prior art).
The claims of U.S. Patent 10,369,264, specifically covering the pure amorphous form and its preparation, are designed to protect the therapeutic and manufacturing advantages associated with this specific solid-state form. This is particularly important if the amorphous form offers significant advantages in terms of drug absorption or stability compared to previously disclosed crystalline forms.
What is the therapeutic significance of amorphous vorapaxar?
The therapeutic significance of amorphous vorapaxar, as addressed by U.S. Patent 10,369,264, lies in its potential for improved pharmacokinetic properties, leading to enhanced patient outcomes.
-
Enhanced Solubility and Dissolution: Amorphous forms of drugs generally exhibit higher intrinsic solubility and faster dissolution rates compared to their crystalline counterparts. This is because amorphous solids lack the ordered molecular lattice structure of crystalline solids, making the molecules more accessible to the solvent. For vorapaxar, an orally administered drug, improved dissolution in the gastrointestinal tract can translate to faster and more complete absorption into the bloodstream.
-
Increased Bioavailability: Higher absorption rates can lead to increased bioavailability, meaning a larger fraction of the administered dose reaches the systemic circulation. This can allow for lower doses to achieve the same therapeutic effect, or it can lead to a more robust and predictable therapeutic response. In the context of vorapaxar, which is used to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease, improved and consistent bioavailability is critical for maintaining effective platelet inhibition.
-
Reduced Variability: The inter-patient variability in drug absorption can be reduced with amorphous forms, leading to more predictable therapeutic levels. This predictability is essential for drugs with a narrow therapeutic index or for those requiring precise and consistent pharmacological effects.
-
Formulation Advantages: The improved solubility of amorphous vorapaxar may also offer advantages in pharmaceutical formulation. It could potentially enable the development of different dosage forms or improve the performance of existing ones. However, the inherent thermodynamic instability of amorphous forms necessitates careful control during manufacturing and formulation to prevent crystallization, as addressed by the patent's focus on "substantially pure amorphous" forms and specific preparation methods.
Vorapaxar's mechanism of action involves blocking the PAR-1 receptor on platelets, thereby inhibiting platelet activation and aggregation. This antiplatelet effect is crucial in preventing blood clots that can lead to heart attacks and strokes. By ensuring a more efficient and consistent delivery of vorapaxar to the body, the amorphous form, as protected by this patent, could enhance the efficacy and reliability of its cardioprotective effects.
Key Takeaways
U.S. Patent 10,369,264 protects a substantially pure amorphous form of vorapaxar and methods for its preparation. This amorphous form is characterized by high purity and the absence of crystalline structures. The patent's claims cover the amorphous compound itself, specific manufacturing processes designed to achieve this form, and pharmaceutical compositions containing it. This intellectual property is crucial for market exclusivity, extending protection for vorapaxar beyond existing patents on the compound and its crystalline forms. The amorphous nature of vorapaxar offers potential therapeutic advantages, including enhanced solubility, dissolution, and bioavailability, which can lead to improved patient outcomes by ensuring more consistent and effective antiplatelet activity.
Frequently Asked Questions
-
What specific problem does U.S. Patent 10,369,264 aim to solve regarding vorapaxar?
The patent aims to solve problems associated with the physical properties of vorapaxar, specifically the development of a substantially pure amorphous form with improved solubility and bioavailability compared to prior crystalline forms, while mitigating the inherent instability of amorphous solids.
-
What are the key criteria for a vorapaxar form to be considered infringing under U.S. Patent 10,369,264?
Infringement would likely occur if a third party manufactures, uses, offers for sale, or sells a vorapaxar product that is in a substantially pure amorphous form (defined as not less than 99.0% by weight and absent crystalline forms by XRPD), or utilizes a method for preparation that is substantially similar to the claimed methods.
-
Can generic versions of vorapaxar be developed if they use a different crystalline form?
Yes, generic versions can be developed using different crystalline forms of vorapaxar, provided those crystalline forms are not covered by other unexpired patents, or if the patent covering those specific crystalline forms has expired. However, a generic product using the amorphous form protected by U.S. Patent 10,369,264 would likely face infringement issues.
-
What is the expected expiration date of U.S. Patent 10,369,264?
The standard term for U.S. Patent 10,369,264, filed on March 20, 2017, is 20 years from the filing date, making its expiration date March 20, 2037, subject to potential patent term adjustments or extensions.
-
Does the patent claim any new therapeutic uses for vorapaxar?
No, U.S. Patent 10,369,264 primarily claims the novel amorphous form of vorapaxar and its preparation methods, not new therapeutic uses. Its significance lies in improving the drug's physical characteristics for better delivery and efficacy within its established therapeutic indications.
Citations
[1] Schering Corporation. (2004). Vorapaxar (U.S. Patent No. 6,703,399). U.S. Patent and Trademark Office.
[2] Schering Corporation. (2014). Vorapaxar crystalline form (U.S. Patent No. 8,877,935). U.S. Patent and Trademark Office.
[3] Merck & Co., Inc. (2019). Substantially pure amorphous vorapaxar and method of preparation (U.S. Patent No. 10,369,264). U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
